dronabinol has been researched along with Substance Withdrawal Syndrome in 186 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 54 (29.03) | 18.7374 |
| 1990's | 20 (10.75) | 18.2507 |
| 2000's | 44 (23.66) | 29.6817 |
| 2010's | 56 (30.11) | 24.3611 |
| 2020's | 12 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Budney, AJ; Connor, JP; Hall, WD; Le Foll, B; Stjepanović, D | 1 |
| Abrahao, KP; Carlson, HB; Gracias, AL; Kesner, AJ; Lovinger, DM; Mateo, Y; Paulsen, RT; Pava, MJ; Ramos-Maciel, S | 1 |
| Davis, KA; Lukas, SE; Zuo, CS | 1 |
| Bedi, G; Cooper, ZD; Foltin, RW; Haney, M; Herrmann, ES; Kingsley, PJ; Marnett, LJ; Patel, S; Reed, SC | 1 |
| Bahji, A; De Aquino, JP; Gómez, O; Sofuoglu, M | 1 |
| Arout, CA; Bari, A; Bellocchio, L; Busquets-Garcia, A; Campistron, G; Caraci, F; Cathala, A; Collins Reed, S; Cooper, ZD; Cota, D; Fabre, S; Felpin, FX; Finlay, DB; Foltin, RW; Glass, M; Haney, M; Hebert-Chatelain, E; Justinova, Z; Kearney-Ramos, T; Levin, FR; Maldonado, R; Marsicano, G; Martín-García, E; Matias, I; Mengel, H; Metna, M; Monlezun, S; Piazza, PV; Redon, B; Revest, JM; Schindler, C; Serrat, R; Shaham, Y; Simon, N; Spampinato, U; Thomsen, LL; Vallée, M; Zanese, M | 1 |
| De La Garza, R; Holst, M; Hussain, MZ; Keller, J; Kosten, TR; Mathai, DS; Patel, MM; Rodgman, C; Verrico, CD | 1 |
| Cheer, JF; Oleson, EB; Peters, KZ | 1 |
| Astbury, D; Baio, G; Bloomfield, MAP; Craft, S; Curran, HV; Freeman, AM; Freeman, TP; Hindocha, C; Kinghorn, J; Lees, R; Mofeez, A; Morgan, CJA; Morrison, PD; O'Ryan, D; Shaban, NDC; Thomas, EM | 1 |
| Dumont, GJH | 1 |
| Bilbao, A; Ferrer, B; Granado, N; Moratalla, R; Pavon, FJ; Rodríguez de Fonseca, F; Serrano, A; Suárez, J; Vadas, E | 1 |
| Kesner, AJ; Lovinger, DM | 1 |
| Barr, MS; George, TP; Goodman, MS; Herman, Y; Kiang, M; Kish, SJ; Rabin, RA; Remington, G; Zakzanis, KK | 1 |
| Barnes, AJ; Fischer, B; George, TP; Huestis, MA; Le Foll, B; Quilty, LC; Rehm, J; Selby, P; Soliman, A; Staios, G; Streiner, DL; Trigo, JM | 1 |
| Lee, DC; Schlienz, NJ; Stitzer, ML; Vandrey, R | 1 |
| Allsop, DJ; Bhardwaj, AK; Bruno, R; Copeland, J; Dunlop, A; Gugusheff, J; Jackson, M; Lintzeris, N; Luksza, J; McGregor, IS; Montebello, M; Phung, N; Sadler, C; Shanahan, M | 1 |
| Crowe, MS; Gross, JD; Jones, MS; Kinsey, SG; McKitrick, AW; Nass, SR; Siderovski, DP; Trexler, KR | 1 |
| Bedi, G; Comer, SD; Cooper, ZD; Foltin, RW; Haney, M; Herrmann, ES; Ramesh, D; Reed, SC | 2 |
| Ahmad, U; Chen, X; Damaj, MI; Donvito, G; Jackson, KJ; Lichtman, AH; McIntosh, JM; Muldoon, PP; Zaveri, NT | 1 |
| McMahon, LR; Schulze, DR; Wilkerson, JL | 1 |
| Abdullah, R; Cravatt, BF; Kinsey, SG; Lichtman, AH; Ramesh, D; Selley, DE; Wise, LE | 1 |
| Bedi, G; Comer, SD; Cooper, ZD; Foltin, RW; Haney, M; Vosburg, SK | 1 |
| Ahmed, I; Muramatsu, RS; Silva, N | 1 |
| Coppola, M; Mondola, R | 1 |
| Barnes, AJ; Bergamaschi, MM; Huestis, MA; Lee, D; Mendu, DR; Milman, G; Vandrey, R | 1 |
| Bar-Hamburger, R; Bloch, M; Bluvstein, I; Miller, H; Rapoport, E; Schreiber, S; Weinstein, AM | 1 |
| Blitzer, RD; Carter, JM; DiNieri, JA; Egervari, G; Hurd, YL; Michaelides, M; Miller, ML; Ren, Y; Sweet, E; Szutorisz, H | 1 |
| Allsop, DJ; Booth, J; Copeland, J; Dunlop, AJ; Holland, RM; Lintzeris, N; McGregor, IS; Montebello, M; Muhleisen, P; Norberg, MM; Rivas, GR; Sadler, C | 1 |
| Bonnet, U; Isbruch, K; Stratmann, U | 1 |
| Antonazzo, KR; Craft, RM; Lefever, TW; Marusich, JA; Wiley, JL | 1 |
| Bonnet, U; Ochwadt, R; Scherbaum, N; Specka, M; Stratmann, U | 1 |
| Frost, DW; Lam, PW | 1 |
| Cridlig, J; Gambier, N; Hingray, C; Laprevote, V; Savenkoff, B; Scala-Bertola, J; Schwan, R | 1 |
| Cravatt, BF; Damaj, MI; Gamage, TF; Ignatowska-Jankowska, BM; Lichtman, AH; Muldoon, PP | 1 |
| Järbe, TU; Makriyannis, A; Nikas, SP; Shukla, VG; Tai, S; Vemuri, K | 1 |
| Allsop, DJ; Copeland, J; Dunlop, A; Lintzeris, N; McGregor, IS | 1 |
| Bisaga, A; Carpenter, KM; Glass, A; Haney, M; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Pavlicova, M; Raby, WN; Sullivan, MA | 1 |
| Craft, RM; Lefever, TW; Marusich, JA; Wiley, JL | 1 |
| Bonnet, U; Borda, T; Scherbaum, N; Specka, M | 1 |
| Babalonis, S; Elayi, SC; Jicha, CJ; Lofwall, MR; Nuzzo, PA; Walsh, SL | 1 |
| Bisaga, A; Brooks, D; Carpenter, KM; Choi, JC; Dakwar, E; Glass, A; Levin, FR; Mahony, A; Mariani, JJ; Nunes, EV; Pavlicova, M; Sullivan, MA | 1 |
| Barnes, AJ; Fischer, B; Gamaleddin, I; Huestis, MA; Lagzdins, D; Le Foll, B; Rehm, J; Selby, P; Trigo, JM | 1 |
| France, CP; Gerak, LR | 1 |
| Becker, JAJ; Kieffer, BL; Le Merrer, J | 1 |
| Babalonis, S; Elayi, SC; Lofwall, MR; Nuzzo, PA; Walsh, SL | 1 |
| Borgiani, P; Calvani, M; Chinello, M; Ciccacci, C; De Giovanni, N; Fucci, N; Locasciulli, A; Mazzoli, F; Scommegna, S; Shardlow, A | 1 |
| Gruber, SA; Pope, HG; Silveri, MM; Simpson, NS; Sneider, JT; Yurgelun-Todd, DA | 1 |
| Haughey, HM; Hutchison, KE; Louis, A; Marshall, E; Schacht, JP | 1 |
| Baraban, JM; Han, S; Miskimon, M; Reti, IM; Rosen, JB | 1 |
| Gorzalka, BB; Hill, MN; Morrish, AC; Riebe, CJ | 1 |
| Abdullah, RA; Carlson, BL; Cravatt, BF; Lichtman, AH; Long, JZ; Ramesh, D; Schlosburg, JE | 1 |
| Nomikos, GG; Panagis, G; Vlachou, S | 1 |
| Cowan, A; Huang, P; Liu-Chen, LY; Unterwald, EM | 1 |
| Hughes, JR; Peters, EN | 1 |
| Gorzalka, BB; Hill, MN; Lee, TT; Riebe, CJ | 1 |
| Huang, P; Kirby, LG; Liu-Chen, LY | 1 |
| McMahon, LR; Stewart, JL | 1 |
| Brown, SA; Hanson, KL; Medina, KL; Schweinsburg, AD; Tapert, SF; Winward, JL | 1 |
| Brooks, DJ; Cheng, W; Levin, FR; Mariani, JJ; Nunes, EV; Pavlicova, M | 1 |
| Strain, EC; Umbricht, A; Vandrey, R | 1 |
| Lichtman, AH; Long, KA; Middleton, LS; Selley, DE; Sim-Selley, LJ; Varvel, SA; Wiebelhaus, JM; Wise, LE | 1 |
| Crane, NA; Crean, RD; Macdonald, K; Mason, BJ; Minassian, A; Tapert, SF | 1 |
| Abdullah, RA; Akbarali, HI; Cravatt, BF; Kinsey, SG; Lichtman, AH; Long, JZ; Nomura, DK; Owens, RA; Ramesh, D; Ross, GR; Schlosburg, JE; Sim-Selley, LJ | 1 |
| Allsop, DJ; Budney, AJ; Copeland, J; Fu, S; Norberg, MM | 1 |
| Bonnet, D; Darwin, WD; Goodwin, RS; Gorelick, DA; Huestis, MA; Kelly, DL; Liu, F; McMahon, RP; Ortemann-Renon, C; Schwilke, E; Schwope, DM | 1 |
| Davies, P; Langford, R; Notcutt, W; Potts, R; Ratcliffe, S | 1 |
| Becker, JA; Befort, K; Darcq, E; Dembele, D; Filliol, D; Gardon, O; Kieffer, BL; Le Merrer, J | 1 |
| Ginsburg, BC; Hruba, L; McMahon, LR; Schulze, DR | 1 |
| Bedi, G; Cooper, ZD; Haney, M | 1 |
| Dow-Edwards, DL; Harte-Hargrove, LC | 1 |
| Comer, SD; Cooper, ZD; Foltin, RW; Haney, M; Hart, CL; Vosburg, SK | 1 |
| Cheer, JF; Oleson, EB | 1 |
| Huestis, MA; Lee, D; Mintzer, MZ; Murray, JA; Stitzer, ML; Vandrey, R | 1 |
| Lichtman, AH; Ramesh, D; Schlosburg, JE; Wiebelhaus, JM | 1 |
| Aguado, F; Espinosa-Parrilla, JF; Ghozland, S; Maldonado, R; Soriano, E | 1 |
| Haney, M | 1 |
| Castañé, A; Kieffer, BL; Maldonado, R; Matifas, A; Robledo, P | 1 |
| Cichewicz, DL; Welch, SP | 1 |
| Anggadiredja, K; Shoyama, Y; Tanaka, H; Watanabe, S; Yamaguchi, T; Yamamoto, T | 2 |
| Borruat, FX; Gaillard, MC | 1 |
| Caberlotto, L; Eriksson, S; Hansson, A; Heilig, M; Rimondini, R | 1 |
| Bennett, A; Foltin, RW; Haney, M; Hart, CL; Nasser, J; Vosburg, SK; Zubaran, C | 1 |
| France, CP; McMahon, LR | 1 |
| Ambrosio, E; Arévalo, C; Cascio, MG; Di Marzo, V; Fernández-Ruiz, J; González, S; Hernández, M; Nicanor, C; Ramos, JA | 1 |
| Cheng, HY; Laviolette, SR; Penninger, JM; van der Kooy, D | 1 |
| Berrendero, F; Castañé, A; Ledent, C; Maldonado, R; Parmentier, M; Soria, G; Valverde, O | 1 |
| Budney, AJ; Hughes, JR; Moore, BA; Vandrey, R | 1 |
| Aso, E; Balerio, GN; Berrendero, F; Maldonado, R; Murtra, P | 1 |
| Lopez-Moreno, JA; Moreno, M; Navarro, M; Rodríguez de Fonseca, F | 1 |
| Bahrenburg, B; Budney, AJ; Hughes, JR; Moore, BA; Vandrey, RG | 1 |
| Maldonado, R; Touriño, C; Valverde, O | 1 |
| Comer, SD; Foltin, RW; Haney, M; Hart, CL; Reed, SC; Vosburg, SK | 1 |
| Cooper, ZD; Haney, M | 1 |
| Garavan, H; Hester, R; Nestor, L; Roberts, G | 1 |
| Berger, M; Hornyak, M; Riemann, D; Schierenbeck, T | 1 |
| Benyamina, A; Blecha, L; Lecacheux, M; Lukasiewcz, M; Reynaud, M | 1 |
| Lutz, B; Moreira, FA | 1 |
| Becker, GL; France, CP; Gerak, LR; Li, JX; McMahon, LR | 1 |
| Bavli, S; Lex, BW; Mello, NK; Mendelson, JH | 1 |
| Fennessy, MR; Taylor, DA | 2 |
| Boren, JJ; Henningfield, JE; Jasinski, DR; Johnson, RE; Lange, WR; Lukas, SE | 1 |
| Fennessy, MR; Taylor, DA; Verberne, AJ | 2 |
| Benowitz, NL; Fredericks, AB | 1 |
| Kaymakçalan, S | 1 |
| Freemon, FR | 1 |
| Karler, R; Turkanis, SA | 1 |
| Domino, EF; Domino, LE; Domino, SE | 1 |
| Jones, RT | 1 |
| Aceto, MD; Lowe, JA; Martin, BR; Scates, SM | 2 |
| Fuentes, JA; Ruiz-Gayo, M; Vela, G | 1 |
| Bonnin, A; Fernández-Ruiz, J; Fuentes, JA; Ruiz-Gayo, M; Vela, G | 1 |
| Simmons, MS; Tashkin, DP | 1 |
| Patrick, SL; Tsou, K; Walker, JM | 1 |
| Bhargava, HN; House, RV; Thomas, PT; Thorat, SN | 1 |
| Carrera, MR; Koob, GF; Navarro, M; Rodríguez de Fonseca, F; Weiss, F | 1 |
| Wickelgren, I | 1 |
| Bakalar, JB; Grinspoon, L; Morgan, JP; Zimmer, L | 1 |
| Cook, SA; Lowe, JA; Martin, BR | 1 |
| Diana, M; Gessa, GL; Melis, M; Muntoni, AL | 1 |
| Arthur, DB; LaVecchia, KL; Lichtman, AH; Martin, BR; Neviaser, ST; Wiley, JL; Wilson, DM | 1 |
| Hanoune, J; Hutcheson, DM; Maldonado, R; Roques, BP; Smadja, C; Tzavara, ET; Valjent, E | 1 |
| Aubert, JF; Beslot, F; Böhme, GA; Cossu, G; Fratta, W; Imperato, A; Ledent, C; Parmentier, M; Pedrazzini, T; Petitet, F; Roques, BP; Valverde, O; Vassart, G | 1 |
| Comer, SD; Fischman, MW; Foltin, RW; Haney, M; Ward, AS | 1 |
| Kouri, EM; Lukas, SE; Pope, HG | 1 |
| Di Chiara, G; Loddo, P; Tanda, G | 1 |
| Beardsley, PM; Martin, BR | 1 |
| Beslot, F; Defer, N; Firmo, C; Hanoune, J; Maldonado, R; Mas, M; Roques, BP; Tzavara, ET; Valjent, E | 1 |
| Cheer, JF; Kendall, DA; Marsden, CA | 1 |
| Maldonado, R; Valjent, E; Valverde, O; Zimmer, A; Zimmer, AM | 1 |
| Force, M; McLemore, G; Roberts, L; Sañudo-Peña, MC; Tsou, K; Walker, JM | 1 |
| Beslot, F; Daugé, V; Fournié-Zaluski, MC; Noble, F; Roques, BP; Valverde, O | 1 |
| Hagiwara, Y; Shoyama, Y; Sugiura, T; Tanaka, H; Waku, K; Watanabe, S; Yamaguchi, T; Yamamoto, T | 1 |
| Lichtman, AH; Loh, HH; Martin, BR; Sheikh, SM | 1 |
| Budney, AJ; Hughes, JR; Moore, BA; Novy, PL | 1 |
| Massi, P; Parolaro, D; Rubino, T; Viganò, D | 1 |
| Bowen, RC; Cui, SS; Gu, GB; Hannesson, DK; Yu, PH; Zhang, X | 1 |
| Filliol, D; Ghozland, S; Kieffer, BL; Maldonado, R; Matthes, HW; Simonin, F | 1 |
| Dhawan, K; Kumar, S; Sharma, A | 1 |
| Stefanis, C | 1 |
| Chesher, GB; Jackson, DM; Malor, R; Zaluzny, SG | 1 |
| Chau-Pham, T; Dewey, WL; Martin, BR; Prnage, AJ | 1 |
| Aceto, MD; Adams, MD; Carney, JM; Dewey, WL; Earnhardt, JT; Martin, BR | 1 |
| Ferraro, DP | 1 |
| Ayhan, IH; Kaymakçalan, S; Tulunay, FC | 1 |
| Bachman, J; Jones, RT | 1 |
| Bourn, WM; Gildea, ML | 1 |
| Bhargava, HN | 3 |
| Craigmill, AL; Sprague, GL | 1 |
| Bachman, J; Benowitz, N; Jones, RT | 1 |
| Paton, WD | 2 |
| Pieper, WA | 1 |
| Wikler, A | 1 |
| Carder, B; Deikel, SM | 1 |
| Ho, BT; Kralik, PM; Matthews, HR | 1 |
| Aiken, JW; Frederickson, RC; Hewes, CR | 1 |
| Friedman, E; Gershon, S; Hine, B; Torrelio, M | 2 |
| Gershon, S; Hine, B; Torrelio, M | 3 |
| Carder, B | 1 |
| McMillan, DE; Snodgrass, SH | 1 |
| Balazs, T; Tocus, EC; Yen-Koo, HC | 1 |
| Balster, RL | 1 |
| Ali, SF; Holson, RR; Paule, MG; Scallet, AC; Slikker, W | 1 |
| Lyman, JL; Mohler, SR | 1 |
| Chait, LD; Fischman, MW; Schuster, CR | 1 |
| Chesher, GB; Jackson, DM | 2 |
| Fennessy, MR; Lewis, SJ; Taylor, DA; Verberne, AJ | 1 |
| Tunving, K | 1 |
| Calder, LD; Karler, R; Turkanis, SA | 1 |
| Balster, RL; Beardsley, PM; Harris, LS | 1 |
| Beck, KJ; Schönhöfer, PS; Zumbé, FJ | 1 |
| Retterstol, N | 1 |
| Nahas, GG; Vourch, G | 1 |
| Kaneto, H; Koida, M; Miyagawa, H; Tsuchie, F | 1 |
| Hirschhorn, ID; Rosecrans, JA | 1 |
21 review(s) available for dronabinol and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Clinical management of cannabis withdrawal.
Topics: Analgesics; Cannabinoid Receptor Agonists; Cannabis; Dronabinol; Hallucinogens; Humans; Marijuana Abuse; Substance Withdrawal Syndrome | 2022 |
Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies.
Topics: Analgesics, Opioid; Cannabinoid Receptor Agonists; Cannabinoids; Cannabis; Dronabinol; Female; Hallucinogens; Humans; Male; Narcotics; Substance Withdrawal Syndrome | 2022 |
A Brain on Cannabinoids: The Role of Dopamine Release in Reward Seeking and Addiction.
Topics: Animals; Brain; Cannabinoid Receptor Agonists; Dopamine; Dronabinol; Endocannabinoids; Humans; Marijuana Abuse; Mice; Reward; Signal Transduction; Substance Withdrawal Syndrome; Synaptic Transmission | 2021 |
Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings.
Topics: Animals; Dronabinol; Drug Tolerance; Endocannabinoids; Humans; Marijuana Abuse; Marijuana Smoking; Receptors, Cannabinoid; Substance Withdrawal Syndrome | 2021 |
Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Marijuana Abuse; Substance Withdrawal Syndrome | 2015 |
Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties.
Topics: Animals; Arachidonic Acids; Brain; Cannabinoids; Conditioning, Classical; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Administration Schedule; Drug Tolerance; Endocannabinoids; Humans; Macaca mulatta; Marijuana Abuse; Mice; Motivation; Polyunsaturated Alkamides; Rats; Receptor, Cannabinoid, CB1; Reward; Self Administration; Substance Withdrawal Syndrome; Synaptic Transmission | 2008 |
A brain on cannabinoids: the role of dopamine release in reward seeking.
Topics: Animals; Brain; Cannabinoid Receptor Agonists; Dopamine; Dronabinol; Endocannabinoids; Humans; Marijuana Abuse; Mice; Reward; Signal Transduction; Substance Withdrawal Syndrome; Synaptic Transmission | 2012 |
Marijuana dependence: not just smoke and mirrors.
Topics: Analgesics; Animals; Dronabinol; Humans; Marijuana Abuse; Smoke; Substance Withdrawal Syndrome | 2011 |
Effects of smoked marijuana in healthy and HIV + marijuana smokers.
Topics: Bupropion; Dronabinol; Eating; HIV Seropositivity; Humans; Marijuana Smoking; Piperazines; Substance Withdrawal Syndrome; Triazoles | 2002 |
Review of the validity and significance of cannabis withdrawal syndrome.
Topics: Ambulatory Care; Animals; Dronabinol; Hospitalization; Humans; Incidence; Marijuana Abuse; Prevalence; Reproducibility of Results; Severity of Illness Index; Substance Withdrawal Syndrome | 2004 |
Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.
Topics: Animals; Brain; Cannabinoids; Dronabinol; Humans; Marijuana Abuse; Motivation; Receptor, Cannabinoid, CB1; Substance Withdrawal Syndrome | 2008 |
Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana.
Topics: Animals; Brain; Cocaine; Disease Models, Animal; Dronabinol; Humans; Illicit Drugs; N-Methyl-3,4-methylenedioxyamphetamine; Polysomnography; Sleep; Sleep Stages; Substance Withdrawal Syndrome; Substance-Related Disorders | 2008 |
Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence.
Topics: Behavior Therapy; Buspirone; Cannabinoids; Cognitive Behavioral Therapy; Combined Modality Therapy; Dronabinol; Humans; Marijuana Abuse; Mianserin; Mirtazapine; Motivation; Piperidines; Psychotherapy; Psychotropic Drugs; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Substance Withdrawal Syndrome | 2008 |
The endocannabinoid system: emotion, learning and addiction.
Topics: Animals; Anxiety; Arousal; Brain; Cannabinoid Receptor Modulators; Cannabinoids; Depression; Dose-Response Relationship, Drug; Dronabinol; Emotions; Endocannabinoids; Fear; Humans; Learning; Marijuana Abuse; Mice; Neurotransmitter Agents; Receptor, Cannabinoid, CB1; Substance Withdrawal Syndrome; Substance-Related Disorders | 2008 |
The addictive potential of cannabis.
Topics: Adolescent; Adult; Animals; Cannabis; Dronabinol; Drug Tolerance; Haplorhini; Humans; Marijuana Abuse; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders | 1981 |
Cannabis and health.
Topics: Abnormalities, Drug-Induced; Animals; Behavior; Cannabis; Carcinogens; Cardiovascular System; Dronabinol; Drug Interactions; Humans; Immunity; Mental Disorders; Motivation; Mutagens; Reproduction; Respiratory System; Substance Withdrawal Syndrome | 1983 |
Preclinical chronic effects: unlearned and learned behavior.
Topics: Animals; Avoidance Learning; Behavior, Animal; Cannabidiol; Cannabinoids; Cannabinol; Conditioning, Operant; Dronabinol; Drug Administration Schedule; Drug Tolerance; Humans; Motor Activity; Reinforcement Schedule; Substance Withdrawal Syndrome | 1977 |
Pharmacology of marijuana.
Topics: Animals; Behavior, Animal; Cannabis; Cognition; Dogs; Dronabinol; Drug Tolerance; Haplorhini; Humans; Mitochondria, Liver; Motor Skills; Neurons; Perception; Phytotherapy; Rats; Smoke; Structure-Activity Relationship; Substance Withdrawal Syndrome; Testosterone | 1975 |
Psychiatric effects of cannabis use.
Topics: Acute Disease; Adolescent; Adolescent Behavior; Adult; Anxiety; Cerebrovascular Circulation; Chronic Disease; Cognition; Depression; Dronabinol; Electroencephalography; Female; Humans; Male; Marijuana Abuse; Mental Disorders; Middle Aged; Motivation; Personality Disorders; Psychoses, Substance-Induced; Substance Withdrawal Syndrome | 1985 |
Cannabis and its problems.
Topics: Abnormalities, Drug-Induced; Animals; Behavior; Blood Pressure; Body Temperature; Cannabis; Cerebral Ventricles; Dronabinol; Drug Tolerance; Electroencephalography; Female; Heart Rate; Humans; Memory; Microsomes, Liver; Phytotherapy; Pregnancy; Psychoses, Substance-Induced; Solubility; Substance Withdrawal Syndrome; Substance-Related Disorders | 1973 |
[Cannabis--clinical pharmacology].
Topics: Administration, Oral; Brain; Cannabis; Dose-Response Relationship, Drug; Dronabinol; Drug Synergism; Drug Tolerance; Heart; Humans; Phytotherapy; Substance Withdrawal Syndrome; Substance-Related Disorders | 1973 |
28 trial(s) available for dronabinol and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers.
Topics: Cannabinoid Receptor Agonists; Cannabis; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Dronabinol; Endocannabinoids; Humans; Marijuana Abuse; Recurrence; Smokers; Substance Withdrawal Syndrome | 2022 |
Signaling-specific inhibition of the CB
Topics: Animals; Cannabis; Double-Blind Method; Dronabinol; Hallucinogens; Marijuana Abuse; Mice; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome | 2023 |
Use of Guanfacine for Cannabis Use Disorder and Related Symptomology.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Affect; Craving; Dronabinol; Female; Guanfacine; Humans; Male; Single-Blind Method; Sleep; Substance Withdrawal Syndrome; Young Adult | 2019 |
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.
Topics: Adolescent; Adult; Bayes Theorem; Cannabidiol; Double-Blind Method; Dronabinol; Female; Hallucinogens; Humans; London; Male; Marijuana Abuse; Marijuana Smoking; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2020 |
Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.
Topics: Adult; Cannabidiol; Cognitive Behavioral Therapy; Craving; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Marijuana Abuse; Middle Aged; Motivation; Pilot Projects; Placebos; Substance Withdrawal Syndrome; Young Adult | 2018 |
Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
Topics: Adult; Australia; Cannabidiol; Cannabinoids; Cognition; Cognitive Behavioral Therapy; Combined Modality Therapy; Craving; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Marijuana Abuse; New South Wales; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome; Treatment Outcome | 2018 |
Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
Topics: Adolescent; Adult; Cannabinoids; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Female; Humans; Male; Marijuana Abuse; Marijuana Smoking; Middle Aged; Substance Withdrawal Syndrome; Young Adult | 2014 |
Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study.
Topics: Adult; Anxiety; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Double-Blind Method; Dronabinol; Female; Humans; Male; Marijuana Abuse; Middle Aged; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Young Adult | 2014 |
Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
Topics: Adult; Australia; Cannabidiol; Cannabinoid Receptor Agonists; Combined Modality Therapy; Double-Blind Method; Dronabinol; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Marijuana Abuse; Middle Aged; Placebo Effect; Placebos; Psychotherapy; Severity of Illness Index; Substance Withdrawal Syndrome; Treatment Outcome | 2014 |
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
Topics: Adult; Cannabinoids; Delayed-Action Preparations; Double-Blind Method; Dronabinol; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Substance Withdrawal Syndrome; Young Adult | 2015 |
Safety of oral dronabinol during opioid withdrawal in humans.
Topics: Administration, Oral; Adolescent; Adult; Analgesics, Opioid; Blood Pressure; Cannabinoid Receptor Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Female; Heart Rate; Humans; Male; Middle Aged; Opioid-Related Disorders; Oxycodone; Pupil; Substance Withdrawal Syndrome; Tachycardia, Sinus; Treatment Outcome; Young Adult | 2015 |
Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Cannabinoid Receptor Agonists; Clonidine; Craving; Double-Blind Method; Dronabinol; Female; Humans; Male; Marijuana Abuse; Medication Adherence; Middle Aged; Narcotic Antagonists; Secondary Prevention; Substance Withdrawal Syndrome | 2016 |
Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.
Topics: Adult; Cannabidiol; Cannabis; Craving; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Marijuana Abuse; Marijuana Smoking; Middle Aged; Plant Extracts; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome; Young Adult | 2016 |
Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.
Topics: Adult; Affect; Anti-Anxiety Agents; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Drug Therapy, Combination; Eating; Female; Humans; Hypnotics and Sedatives; Male; Marijuana Abuse; Marijuana Smoking; Middle Aged; Pyridines; Sleep; Substance Withdrawal Syndrome; Young Adult; Zolpidem | 2016 |
Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.
Topics: Administration, Oral; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Oxycodone; Receptor, Cannabinoid, CB1; Substance Withdrawal Syndrome; Young Adult | 2016 |
Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Behavior, Addictive; Cannabinoids; Double-Blind Method; Dronabinol; Drug Administration Schedule; Female; Humans; Male; Marijuana Abuse; Marijuana Smoking; Middle Aged; Placebos; Psychotherapy; Psychotropic Drugs; Substance Withdrawal Syndrome | 2011 |
Increased blood pressure after abrupt cessation of daily cannabis use.
Topics: Adult; Blood Pressure; Cross-Over Studies; Dronabinol; Female; Heart Rate; Humans; Hypnotics and Sedatives; Male; Marijuana Abuse; Pyridines; Substance Withdrawal Syndrome; Zolpidem | 2011 |
Antagonist-elicited cannabis withdrawal in humans.
Topics: Adult; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Humans; Male; Marijuana Abuse; Mass Spectrometry; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance Withdrawal Syndrome; Young Adult | 2011 |
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).
Topics: Aged; Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Muscle Spasticity; Placebos; Plant Extracts; Substance Withdrawal Syndrome | 2012 |
Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.
Topics: Adult; Affect; Analysis of Variance; Biological Availability; Blood Pressure; Cannabinoid Receptor Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Female; Heart Rate; Humans; Male; Marijuana Abuse; Middle Aged; Placebos; Psychomotor Performance; Secondary Prevention; Substance Withdrawal Syndrome; Time Factors; Young Adult | 2013 |
A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.
Topics: Adult; Affect; Analysis of Variance; Anorexia; Antipsychotic Agents; Dibenzothiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Female; Humans; Male; Marijuana Abuse; Middle Aged; Neuropsychological Tests; Placebos; Psychomotor Performance; Quetiapine Fumarate; Secondary Prevention; Self Administration; Sleep Wake Disorders; Substance Withdrawal Syndrome; Weight Loss; Young Adult | 2013 |
The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users.
Topics: Adolescent; Adult; Cannabis; Cross-Over Studies; Dose-Response Relationship, Drug; Dronabinol; Drug Administration Schedule; Eating; Female; Heart Rate; Humans; Male; Marijuana Abuse; Middle Aged; Sleep; Substance Withdrawal Syndrome | 2013 |
Marijuana withdrawal in humans: effects of oral THC or divalproex.
Topics: Adult; Affect; Analysis of Variance; Anticonvulsants; Body Weight; Cannabis; Double-Blind Method; Dronabinol; Eating; Humans; Male; Neuropsychological Tests; Psychomotor Performance; Psychotropic Drugs; Sleep; Smoking; Social Behavior; Substance Withdrawal Syndrome; Surveys and Questionnaires; Time Factors; Valproic Acid | 2004 |
Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.
Topics: Adrenergic alpha-Agonists; Adult; Affect; Appetite; Attention; Cannabinoids; Clonidine; Double-Blind Method; Dronabinol; Drug Therapy, Combination; Humans; Male; Marijuana Abuse; Mental Recall; Psychomotor Performance; Psychotropic Drugs; Secondary Prevention; Sleep; Substance Withdrawal Syndrome | 2008 |
The effect of chronically administered delta-9-tetrahydrocannabinol upon the polygraphically monitored sleep of normal volunteers.
Topics: Adult; Dronabinol; Humans; Male; Sleep; Sleep Stages; Sleep Wake Disorders; Sleep, REM; Substance Withdrawal Syndrome | 1982 |
Marijuana abstinence effects in marijuana smokers maintained in their home environment.
Topics: Adolescent; Adult; Affective Symptoms; Aggression; Ambulatory Care; Behavior, Addictive; Creatinine; Dronabinol; Feeding and Eating Disorders; Female; Humans; Male; Marijuana Abuse; Middle Aged; Personality Inventory; Psychomotor Agitation; Severity of Illness Index; Sleep Wake Disorders; Substance Abuse Detection; Substance Withdrawal Syndrome; Weight Loss | 2001 |
Clinical studies of cannabis tolerance and dependence.
Topics: Adult; Cannabis; Clinical Trials as Topic; Dronabinol; Drug Administration Schedule; Drug Tolerance; Electroencephalography; Humans; Male; Psychopharmacology; Substance Withdrawal Syndrome; Substance-Related Disorders; Surveys and Questionnaires; Time Factors | 1976 |
'Hangover' effects the morning after marijuana smoking.
Topics: Adult; Affect; Arousal; Attention; Carbon Monoxide; Dronabinol; Heart Rate; Humans; Male; Mental Recall; Psychomotor Performance; Substance Withdrawal Syndrome | 1985 |
137 other study(ies) available for dronabinol and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Changes in striatal dopamine release, sleep, and behavior during spontaneous Δ-9-tetrahydrocannabinol abstinence in male and female mice.
Topics: Animals; Cannabinoid Receptor Agonists; Dopamine; Dronabinol; Female; Male; Mice; Sleep; Substance Withdrawal Syndrome | 2022 |
Lower dACC glutamate in cannabis users during early phase abstinence.
Topics: Cannabinoid Receptor Agonists; Cannabis; Dronabinol; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus Cinguli; Hallucinogens; Humans; Protons; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome | 2022 |
[Nabiximols as a substitute for cannabis].
Topics: Analgesics; Cannabidiol; Cannabis; Clinical Trials as Topic; Dronabinol; Drug Combinations; Female; Humans; Male; Marijuana Abuse; Nasal Sprays; Substance Withdrawal Syndrome | 2020 |
Genetic deletion of dopamine D1 receptors increases the sensitivity to cannabinoid CB1 receptor antagonist-precipitated withdrawal when compared with wild-type littermates: studies in female mice repeatedly exposed to the Spice cannabinoid HU-210.
Topics: Animals; Behavior, Animal; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Dose-Response Relationship, Drug; Dronabinol; Female; Male; Mice; Mice, Knockout; Motor Activity; Receptor, Cannabinoid, CB1; Receptors, Dopamine D1; Receptors, Dopamine D2; Rimonabant; Substance Withdrawal Syndrome | 2021 |
Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls.
Topics: Adult; Cognition Disorders; Creatinine; Cross-Sectional Studies; Dronabinol; Female; Humans; Male; Marijuana Abuse; Neuropsychological Tests; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia; Self Report; Statistics, Nonparametric; Substance Withdrawal Syndrome; Time Factors; Young Adult | 2017 |
The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
Topics: Administration, Oral; Adult; Cannabinoid Receptor Agonists; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Drug Administration Schedule; Female; Humans; Male; Marijuana Abuse; Marijuana Smoking; Middle Aged; Self Administration; Substance Withdrawal Syndrome; Young Adult | 2018 |
Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.
Topics: Animals; Behavior, Animal; Benzodioxoles; Cannabinoid Receptor Agonists; Dronabinol; Indoles; Male; Marijuana Abuse; Mice; Mice, Inbred C57BL; Naphthalenes; Piperidines; Pyrazoles; Rimonabant; Substance Withdrawal Syndrome | 2018 |
Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse.
Topics: Adult; Cigarette Smoking; Comorbidity; Dronabinol; Female; Humans; Male; Marijuana Abuse; Nicotine; Nicotinic Agonists; Smoking Cessation; Smoking Cessation Agents; Substance Withdrawal Syndrome; Varenicline; Young Adult | 2019 |
Neuronal nicotinic acetylcholine receptors mediate ∆
Topics: Animals; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dronabinol; Humans; Marijuana Abuse; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, Nicotinic; Rimonabant; Substance Withdrawal Syndrome | 2020 |
Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments.
Topics: Administration, Intravenous; Animals; Disease Models, Animal; Dronabinol; Drug Tolerance; Female; Hallucinogens; Humans; Macaca mulatta; Male; Motor Activity; Rimonabant; Substance Withdrawal Syndrome | 2019 |
Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arachidonic Acids; Benzodioxoles; Brain Chemistry; Cyclohexanols; Diclofenac; Dose-Response Relationship, Drug; Dronabinol; Drug Tolerance; Endocannabinoids; Glycerides; Guanosine 5'-O-(3-Thiotriphosphate); Male; Mice; Mice, Inbred C57BL; Monoacylglycerol Lipases; Pain Measurement; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Stomach Ulcer; Substance Withdrawal Syndrome; Substance-Related Disorders | 2013 |
Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.
Topics: Adult; Dose-Response Relationship, Drug; Dronabinol; Female; Humans; Male; Marijuana Abuse; Marijuana Smoking; Psychomotor Performance; Secondary Prevention; Self Administration; Substance Withdrawal Syndrome; Young Adult | 2013 |
Suspected dronabinol withdrawal in an elderly cannabis-naive medically ill patient.
Topics: Aged; Dronabinol; Female; Humans; Psychotropic Drugs; Substance Withdrawal Syndrome | 2013 |
Palmitoylethanolamide: from endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence.
Topics: Amides; Arachidonic Acids; Dronabinol; Endocannabinoids; Ethanolamines; Humans; Marijuana Abuse; Models, Biological; Molecular Structure; Palmitic Acids; Polyunsaturated Alkamides; Substance Withdrawal Syndrome; TRPV Cation Channels | 2013 |
Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation.
Topics: Animals; Compulsive Behavior; Corpus Striatum; Dronabinol; Drug-Seeking Behavior; Female; Heroin Dependence; Male; Maternal Exposure; Neuronal Plasticity; Paternal Exposure; Psychotropic Drugs; Rats; Rats, Long-Evans; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Stereotyped Behavior; Substance Withdrawal Syndrome; Synapses | 2014 |
[No opiates against cannabis hyperemesis syndrome].
Topics: Adult; Antiemetics; Dronabinol; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Germany; Humans; Infusions, Intravenous; Male; Marijuana Abuse; Methadone; Morphine; Opioid-Related Disorders; Substance Abuse Treatment Centers; Substance Withdrawal Syndrome; Vomiting | 2014 |
Evaluation of sex differences in cannabinoid dependence.
Topics: Acoustic Stimulation; Animals; Cannabinoids; Dronabinol; Female; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Sensory Gating; Sex Characteristics; Substance Withdrawal Syndrome; Substance-Related Disorders | 2014 |
Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum.
Topics: Adult; Dronabinol; Female; Humans; Male; Marijuana Abuse; Patient Admission; Prognosis; Prospective Studies; Statistics as Topic; Substance Withdrawal Syndrome; Young Adult | 2014 |
Nabilone therapy for cannabis withdrawal presenting as protracted nausea and vomiting.
Topics: Cannabinoids; Cannabis; Diagnosis, Differential; Dronabinol; Female; Humans; Nausea; Substance Withdrawal Syndrome; Vomiting; Young Adult | 2014 |
Early withdrawal effects in a heavy cannabis smoker during hemodialysis.
Topics: Adult; Dronabinol; Humans; Male; Marijuana Abuse; Marijuana Smoking; Pain Measurement; Renal Dialysis; Renal Insufficiency; Substance Withdrawal Syndrome | 2015 |
Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice.
Topics: Acetamides; Amidohydrolases; Animals; Avoidance Learning; Benzodioxoles; Carbamates; Conditioning, Psychological; Dronabinol; Endocannabinoids; Enzyme Inhibitors; Male; Mice; Monoacylglycerol Lipases; Morphine; Naloxone; Piperidines; Pyridines; Substance Withdrawal Syndrome | 2015 |
Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Topics: Animals; Body Temperature; Cannabinoid Receptor Antagonists; Cannabinoids; Disease Models, Animal; Dronabinol; Drug Tolerance; Male; Mice; Morpholines; Motor Activity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance Withdrawal Syndrome | 2015 |
The impact of gonadal hormones on cannabinoid dependence.
Topics: Animals; Body Weight; Castration; Disease Models, Animal; Dronabinol; Drug Tolerance; Estrous Cycle; Female; Gonadal Hormones; Hormone Replacement Therapy; Male; Marijuana Abuse; Motor Activity; Pain Measurement; Rats; Rats, Sprague-Dawley; Reflex, Startle; Sex Characteristics; Substance Withdrawal Syndrome; Time Factors | 2015 |
Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification (Part II): Psychiatric complaints and their relation to delta-9-tetrahydrocannabinol and its metabolites in serum.
Topics: Cannabis; Comorbidity; Dronabinol; Female; Humans; Inpatients; Male; Marijuana Abuse; Mental Disorders; Prospective Studies; Psychiatric Status Rating Scales; Substance Withdrawal Syndrome | 2015 |
Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Analgesics, Opioid; Animals; Benzoxazines; Cannabinoid Receptor Agonists; Cyclohexanols; Dose-Response Relationship, Drug; Dronabinol; Drug Tolerance; Heart Rate; Macaca mulatta; Morphine; Morpholines; Naphthalenes; Opioid-Related Disorders; Pain Measurement; Substance Withdrawal Syndrome | 2016 |
Differential behavioral and molecular alterations upon protracted abstinence from cocaine versus morphine, nicotine, THC and alcohol.
Topics: Alcohol Abstinence; Amygdala; Analgesics, Opioid; Animals; Anxiety; Behavior, Animal; Brain; Cannabinoid Receptor Agonists; Central Nervous System Depressants; Cocaine; Dopamine Uptake Inhibitors; Dronabinol; Drug-Seeking Behavior; Emotions; Ethanol; Male; Mice; Morphine; Motivation; Nicotine; Nicotinic Agonists; Proto-Oncogene Proteins c-fos; Social Behavior; Stereotyped Behavior; Substance Withdrawal Syndrome | 2017 |
Cannabinoid Poisoning by Hemp Seed Oil in a Child.
Topics: Cannabinoids; Cannabis; Child, Preschool; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Dronabinol; Humans; Infusions, Intravenous; Male; Plant Oils; Poisoning; Seeds; Substance Withdrawal Syndrome; Treatment Outcome | 2017 |
Differences in regional blood volume during a 28-day period of abstinence in chronic cannabis smokers.
Topics: Adult; Blood Volume; Brain; Brain Mapping; Dronabinol; Female; Functional Laterality; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Marijuana Abuse; Middle Aged; Regional Blood Flow; Substance Withdrawal Syndrome; Time Factors | 2008 |
Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes.
Topics: Adolescent; Adult; Amidohydrolases; Behavior, Addictive; Cues; Dronabinol; Female; Genotype; Humans; Male; Marijuana Abuse; Motivation; Polymorphism, Single Nucleotide; Receptor, Cannabinoid, CB1; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2008 |
Nicotine and Delta(9)-tetrahydrocannabinol withdrawal induce Narp in the central nucleus of the amygdala.
Topics: Amygdala; Animals; C-Reactive Protein; Cell Count; Dronabinol; Male; Morpholines; Nerve Tissue Proteins; Neurons; Nicotine; Pyrazoles; Rats; Stress, Psychological; Substance Withdrawal Syndrome | 2009 |
Protracted cannabinoid administration elicits antidepressant behavioral responses in rats: role of gender and noradrenergic transmission.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Cannabinoids; Desipramine; Dronabinol; Female; Male; Norepinephrine; Piperidines; Prazosin; Propranolol; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Sex Characteristics; Substance Withdrawal Syndrome; Swimming; Synaptic Transmission | 2009 |
Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.
Topics: Amidohydrolases; Animals; Benzamides; Benzodioxoles; Cannabinoid Receptor Modulators; Carbamates; Dronabinol; Endocannabinoids; Enzyme Inhibitors; Hallucinogens; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monoacylglycerol Lipases; Motor Activity; Piperidines; Postural Balance; Psychomotor Performance; Pyrazoles; Rimonabant; Substance Withdrawal Syndrome | 2009 |
Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice.
Topics: Analysis of Variance; Animals; Dronabinol; Dyskinesia, Drug-Induced; Forelimb; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Piperidines; Psychotropic Drugs; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance Withdrawal Syndrome; Tremor | 2009 |
Daily marijuana users with past alcohol problems increase alcohol consumption during marijuana abstinence.
Topics: Adolescent; Adult; Aggression; Alcohol Drinking; Alcoholism; Anger; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dronabinol; Educational Status; Employment; Feeding and Eating Disorders; Female; Humans; Male; Marijuana Abuse; Marital Status; Patient Selection; Sleep Wake Disorders; Substance Withdrawal Syndrome | 2010 |
Precipitated withdrawal counters the adverse effects of subchronic cannabinoid administration on male rat sexual behavior.
Topics: Animals; Copulation; Dose-Response Relationship, Drug; Dronabinol; Female; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Substance Withdrawal Syndrome | 2010 |
Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze.
Topics: Animals; Anxiety; Dronabinol; Emotions; Male; Maze Learning; Mice; Mice, Inbred ICR; Piperidines; Psychotropic Drugs; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance Withdrawal Syndrome | 2010 |
Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
Topics: Adrenergic Agonists; Animals; Behavior, Animal; Benzoxazines; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Clonidine; Cyclohexanols; Discrimination, Psychological; Dronabinol; Female; Heart Rate; Macaca mulatta; Male; Morpholines; Motor Activity; Naphthalenes; Piperidines; Pyrazoles; Rimonabant; Substance Withdrawal Syndrome | 2010 |
Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence.
Topics: Adolescent; Attention; Cannabis; Case-Control Studies; Cognition; Dronabinol; Female; Humans; Learning; Learning Disabilities; Longitudinal Studies; Male; Marijuana Abuse; Memory, Short-Term; Neuropsychological Tests; Substance Withdrawal Syndrome; Young Adult | 2010 |
delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory.
Topics: Animals; Dose-Response Relationship, Drug; Dronabinol; Male; Marijuana Abuse; Maze Learning; Memory Disorders; Memory, Short-Term; Mice; Mice, Inbred C57BL; Piperidines; Pyrazoles; Rimonabant; Spatial Behavior; Substance Withdrawal Syndrome | 2011 |
Effects of chronic, heavy cannabis use on executive functions.
Topics: Adult; Affect; Attention; Decision Making; Dronabinol; Executive Function; Female; Humans; Inhibition, Psychological; Marijuana Abuse; Neuropsychological Tests; Rehabilitation, Vocational; Substance Abuse Detection; Substance Withdrawal Syndrome; Token Economy | 2011 |
Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.
Topics: Amidohydrolases; Animals; Arachidonic Acid; Behavior, Animal; Benzodioxoles; Brain Chemistry; Cannabinoid Receptor Modulators; Diarrhea; Dronabinol; Electric Stimulation; Endocannabinoids; Hydrolysis; Ileum; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Monoacylglycerol Lipases; Morphine Dependence; Muscle Contraction; Naloxone; Narcotic Antagonists; Piperidines; Prostaglandins; Pyridines; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Substance Withdrawal Syndrome; Weight Loss | 2011 |
The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress.
Topics: Adult; Cannabis; Dronabinol; Female; Forecasting; Humans; Male; Marijuana Abuse; Middle Aged; Psychiatric Status Rating Scales; Psychometrics; Psychotropic Drugs; Reproducibility of Results; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2011 |
Protracted abstinence from distinct drugs of abuse shows regulation of a common gene network.
Topics: Amygdala; Animals; Behavior, Addictive; Brain; Cluster Analysis; Disease Models, Animal; Dronabinol; Ethanol; Gene Expression; Gene Regulatory Networks; Male; Mice; Mice, Inbred C57BL; Morphine; Nicotine; Principal Component Analysis; Real-Time Polymerase Chain Reaction; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Substance-Related Disorders; Temperance; Time; Transcriptional Activation | 2012 |
JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys.
Topics: Animals; Behavior, Animal; Conditioning, Operant; Data Interpretation, Statistical; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Dronabinol; Female; Hallucinogens; Illicit Drugs; Indoles; Macaca mulatta; Male; Marijuana Abuse; Naphthalenes; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance Withdrawal Syndrome | 2012 |
Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Dose-Response Relationship, Drug; Dronabinol; Female; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Sex Factors; Substance Withdrawal Syndrome | 2012 |
Spontaneous network activity of cerebellar granule neurons: impairment by in vivo chronic cannabinoid administration.
Topics: Animals; Cannabinoids; Cerebellum; Dronabinol; In Vitro Techniques; Mice; Nerve Net; Neurons; Receptors, Cannabinoid; Receptors, Drug; Substance Withdrawal Syndrome; Synaptic Transmission | 2002 |
Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice.
Topics: Analgesics, Non-Narcotic; Animals; Cannabinoids; Dronabinol; Drug Tolerance; Euphoria; Mice; Mice, Knockout; Psychotropic Drugs; Receptors, Opioid, delta; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Substance-Related Disorders | 2003 |
Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol.
Topics: Administration, Oral; Analgesics; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Dronabinol; Drug Tolerance; Hallucinogens; Male; Mice; Mice, Inbred ICR; Morphine; Morphine Dependence; Naloxone; Narcotic Antagonists; Substance Withdrawal Syndrome | 2003 |
Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
Topics: Animals; Cannabinoids; Dinoprostone; Dose-Response Relationship, Drug; Dronabinol; Male; Mice; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome | 2003 |
Persisting visual hallucinations and illusions in previously drug-addicted patients.
Topics: Adolescent; Adult; Alcohol Drinking; Chronic Disease; Dronabinol; Female; Follow-Up Studies; Hallucinations; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Marijuana Abuse; Optical Illusions; Substance Withdrawal Syndrome; Substance-Related Disorders | 2003 |
Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?
Topics: Amygdala; Analysis of Variance; Animals; Behavior, Animal; Cannabinoids; Corticotropin-Releasing Hormone; Dose-Response Relationship, Drug; Dronabinol; Drug Administration Schedule; Drug Tolerance; Excitatory Amino Acid Antagonists; Gene Expression Regulation; In Situ Hybridization; Locomotion; Male; Maze Learning; Neostriatum; Neuropeptide Y; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptors, Neuropeptide Y; Rimonabant; RNA, Messenger; Substance Withdrawal Syndrome; Time Factors | 2004 |
Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
Topics: Anesthetics; Animals; Behavior, Animal; Cannabinoids; Cocaine; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Ketamine; Macaca mulatta; Male; Photic Stimulation; Piperidines; Psychotropic Drugs; Pyrazoles; Rimonabant; Substance Withdrawal Syndrome | 2003 |
Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
Topics: Animals; Arachidonic Acids; Behavior, Animal; Brain; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Corticosterone; Dronabinol; Drug Administration Schedule; Drug Tolerance; Endocannabinoids; Glycerides; Male; Paraventricular Hypothalamic Nucleus; Piperidines; Polyunsaturated Alkamides; Prolactin; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Corticotropin-Releasing Hormone; Rimonabant; RNA, Messenger; Substance Withdrawal Syndrome | 2004 |
DREAM ablation selectively alters THC place aversion and analgesia but leaves intact the motivational and analgesic effects of morphine.
Topics: Analgesia; Analgesics; Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Cocaine; Conditioning, Operant; Dose-Response Relationship, Drug; Dronabinol; Lithium Chloride; Male; Mice; Mice, Knockout; Morphine; Motivation; Motor Activity; Naloxone; Narcotic Antagonists; Reaction Time; Repressor Proteins; Substance Withdrawal Syndrome; Transcription Factors | 2004 |
Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC.
Topics: Animals; Conditioning, Psychological; Dronabinol; Mice; Mice, Knockout; Pain Measurement; Receptor, Adenosine A2A; Substance Withdrawal Syndrome; Substance-Related Disorders | 2004 |
Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice.
Topics: Analgesics, Non-Narcotic; Analysis of Variance; Animals; Autoradiography; Behavior, Animal; Benzoxazines; Brain; Calcium Channel Blockers; Cell Count; Conditioning, Operant; Dronabinol; Drug Administration Schedule; Drug Interactions; Immunohistochemistry; In Vitro Techniques; Male; Mecamylamine; Mice; Morpholines; Motivation; Naloxone; Naphthalenes; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Proto-Oncogene Proteins c-fos; Radioligand Assay; Substance Withdrawal Syndrome | 2004 |
Behavioural effects of quinpirole following withdrawal of chronic treatment with the CB1 agonist, HU-210, in rats.
Topics: Animals; Behavior, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dronabinol; Male; Motor Activity; Quinpirole; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Substance Withdrawal Syndrome; Time Factors | 2005 |
Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: a quasi abstinence approach.
Topics: Animals; Behavior, Animal; Cannabinoids; Cyclooxygenase Inhibitors; Diclofenac; Dronabinol; Male; Mice; Piperidines; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rimonabant; Substance Withdrawal Syndrome; Weight Loss | 2005 |
Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms.
Topics: Administration, Oral; Adult; Cannabis; Dose-Response Relationship, Drug; Dronabinol; Female; Hallucinogens; Humans; Male; Marijuana Abuse; Middle Aged; Severity of Illness Index; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2007 |
MDMA attenuates THC withdrawal syndrome in mice.
Topics: Animals; Brain; Cannabinoid Receptor Antagonists; Dopamine; Dose-Response Relationship, Drug; Dronabinol; Male; Mice; Mice, Inbred Strains; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Piperidines; Pyrazoles; Rimonabant; Serotonin; Substance Withdrawal Syndrome | 2007 |
Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.
Topics: Adult; Data Interpretation, Statistical; Dronabinol; Face; Female; Hallucinogens; Humans; Image Processing, Computer-Assisted; Learning Disabilities; Magnetic Resonance Imaging; Male; Marijuana Abuse; Memory; Memory Disorders; Oxygen; Parahippocampal Gyrus; Prefrontal Cortex; Psychomotor Performance; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2008 |
Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.
Topics: Analgesics; Analgesics, Opioid; Animals; Data Interpretation, Statistical; Discrimination, Psychological; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Heroin; Hot Temperature; Hypnotics and Sedatives; Macaca mulatta; Male; Midazolam; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Pain Measurement; Receptors, Opioid, mu; Substance Withdrawal Syndrome | 2008 |
Marijuana withdrawal syndrome in a woman.
Topics: Adult; Dose-Response Relationship, Drug; Dronabinol; Female; Humans; Marijuana Abuse; Substance Withdrawal Syndrome | 1984 |
Time-course of the effects of chronic delta 9-tetrahydrocannabinol on behaviour, body temperature, brain amines and withdrawal-like behaviour in the rat.
Topics: Animals; Behavior, Animal; Biogenic Amines; Body Temperature; Brain Chemistry; Clomipramine; Dronabinol; Humans; Male; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome; Time Factors | 1982 |
Progress report from the NIDA Addiction Research Center, Baltimore, Maryland.
Topics: Anti-Anxiety Agents; Buprenorphine; Double-Blind Method; Dronabinol; Drug Synergism; Heroin Dependence; Humans; Marijuana Abuse; Methadone; Opioid-Related Disorders; Pentazocine; Smoking Prevention; Substance Withdrawal Syndrome; Substance-Related Disorders; Tripelennamine | 1984 |
Withdrawal-like behaviour induced by inhibitors of biogenic amine reuptake in rats treated chronically with delta 9-tetrahydrocannabinol.
Topics: Animals; Biogenic Amines; Body Weight; Clomipramine; Dronabinol; Eating; Fluoxetine; Humans; Imipramine; Male; Rats; Substance Withdrawal Syndrome; Time Factors | 1980 |
An abstinence syndrome following chronic administration of delta-9-terahydrocannabinol in rhesus monkeys.
Topics: Animals; Behavior, Animal; Dronabinol; Drug Tolerance; Humans; Macaca mulatta; Male; Substance Withdrawal Syndrome | 1980 |
Attenuation of delta 9-tetrahydrocannabinol-induced withdrawal-like behaviour by delta 9-tetrahydrocannabinol.
Topics: Animals; Behavior, Animal; Clomipramine; Dronabinol; Humans; Male; Rats; Substance Withdrawal Syndrome | 1981 |
Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice.
Topics: Animals; Anticonvulsants; Cannabidiol; Cannabinoids; Dronabinol; Drug Tolerance; Electroshock; Humans; Male; Mice; Mice, Inbred ICR; Substance Withdrawal Syndrome | 1980 |
Is there "reverse tolerance" to marijuana?
Topics: Adolescent; Adult; Brain; Cannabinoids; Child; Dronabinol; Drug Tolerance; Humans; Marijuana Abuse; Substance Withdrawal Syndrome | 1983 |
Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
Topics: Animals; Dronabinol; Male; Piperidines; Psychotropic Drugs; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome | 1995 |
Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine.
Topics: Animals; Arachidonic Acids; Body Weight; Dose-Response Relationship, Drug; Dronabinol; Endocannabinoids; Male; Mice; Mice, Inbred Strains; Morphine; Naloxone; Polyunsaturated Alkamides; Substance Withdrawal Syndrome | 1995 |
Perinatal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) leads to changes in opioid-related behavioral patterns in rats.
Topics: Analgesics; Animals; Animals, Newborn; Behavior, Animal; Dronabinol; Female; Male; Morphine; Naloxone; Narcotics; Pain Threshold; Rats; Rats, Wistar; Sex Characteristics; Substance Withdrawal Syndrome | 1995 |
The relationship of tobacco and marijuana smoking characteristics.
Topics: Adult; Dronabinol; Female; Humans; Male; Marijuana Smoking; Middle Aged; Nicotiana; Plants, Toxic; Respiratory Function Tests; Smoking; Smoking Cessation; Substance Withdrawal Syndrome | 1995 |
Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
Topics: Animals; Behavior, Animal; Dronabinol; Hallucinogens; Injections, Intraperitoneal; Motor Activity; Piperidines; Pyrazoles; Rats; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome; Vocalization, Animal | 1995 |
Cellular immune function in mice tolerant to or abstinent from l-trans-delta 9-tetrahydrocannabinol.
Topics: Analgesics; Animals; B-Lymphocytes; Body Weight; Cell Division; Cytokines; Dronabinol; Drug Tolerance; Female; Immunity, Cellular; Killer Cells, Natural; Male; Mice; Mice, Inbred Strains; Organ Size; Psychotropic Drugs; Spleen; Substance Withdrawal Syndrome; T-Lymphocytes, Cytotoxic | 1996 |
Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
Topics: Animals; Body Weight; Dronabinol; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome | 1996 |
Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal.
Topics: Amygdala; Animals; Anxiety; Behavior, Animal; Brain; Corticosterone; Corticotropin-Releasing Hormone; Dronabinol; Male; Microdialysis; Piperidines; Proto-Oncogene Proteins c-fos; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome | 1997 |
Marijuana: harder than thought?
Topics: Amygdala; Animals; Brain; Cannabis; Corticotropin-Releasing Hormone; Dopamine; Dronabinol; Humans; Naloxone; Nucleus Accumbens; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders | 1997 |
Marijuana addiction.
Topics: Animals; Cannabis; Dopamine; Dronabinol; Humans; Nucleus Accumbens; Rats; Reward; Substance Withdrawal Syndrome; Substance-Related Disorders | 1997 |
CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
Topics: Analysis of Variance; Animals; Antiemetics; Appetite Stimulants; Behavior, Animal; Dronabinol; Hallucinogens; Male; Mice; Mice, Inbred ICR; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome | 1998 |
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
Topics: Animals; Behavior, Animal; Dopamine; Dronabinol; Electrophysiology; Limbic System; Male; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Substance-Related Disorders; Synaptic Transmission | 1998 |
Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
Topics: Animals; Arachidonic Acids; Behavior, Animal; Cannabinoids; Dogs; Dronabinol; Endocannabinoids; Female; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rimonabant; Substance Withdrawal Syndrome; Time Factors | 1998 |
Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol.
Topics: Analysis of Variance; Animals; Body Temperature; Body Weight; Conditioning, Psychological; Cyclic AMP; Dronabinol; Drug Interactions; Hallucinogens; Hypothermia; In Vitro Techniques; Male; Mice; Motivation; Narcotics; Pain Measurement; Piperidines; Pyrazoles; Rimonabant; Substance Withdrawal Syndrome | 1998 |
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Blood Pressure; Body Temperature; Cannabinoids; Dronabinol; Heart Rate; Mice; Mice, Knockout; Morphine; Motor Activity; Narcotics; Opioid-Related Disorders; Pain Threshold; Receptors, Cannabinoid; Receptors, Drug; Receptors, Opioid, kappa; Reinforcement, Psychology; Substance Withdrawal Syndrome | 1999 |
Abstinence symptoms following oral THC administration to humans.
Topics: Administration, Oral; Adult; Appetite; Appetite Stimulants; Cannabis; Dronabinol; Drug Tolerance; Eating; Female; Humans; Male; Psychomotor Performance; Social Behavior; Substance Withdrawal Syndrome; Substance-Related Disorders; Surveys and Questionnaires | 1999 |
Changes in aggressive behavior during withdrawal from long-term marijuana use.
Topics: Adult; Aggression; Analysis of Variance; Biomarkers; Case-Control Studies; Dronabinol; Female; Humans; Male; Marijuana Abuse; Middle Aged; Substance Withdrawal Syndrome | 1999 |
Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Topics: Animals; Behavior, Animal; Cannabinoids; Dopamine; Dronabinol; Hallucinogens; Male; Microdialysis; Nucleus Accumbens; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome; Substance-Related Disorders | 1999 |
Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
Topics: Animals; Dose-Response Relationship, Drug; Dronabinol; Male; Piperidines; Psychotropic Drugs; Pyrazoles; Rats; Rats, Long-Evans; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome; Substance-Related Disorders | 2000 |
Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenylyl Cyclases; Animals; Behavior, Animal; Cerebellum; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dronabinol; Enzyme Activation; Hallucinogens; Injections; Injections, Intraventricular; Male; Mice; Piperidines; Pyrazoles; Receptors, Drug; Rimonabant; Stereotaxic Techniques; Substance Withdrawal Syndrome; Up-Regulation | 2000 |
Cannabinoid receptors and reward in the rat: a conditioned place preference study.
Topics: Animals; Avoidance Learning; Cannabinoids; Conditioning, Psychological; Dronabinol; Male; Piperidines; Pyrazoles; Rats; Receptors, Cannabinoid; Receptors, Drug; Reward; Rimonabant; Substance Withdrawal Syndrome | 2000 |
Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice.
Topics: Acute Disease; Analysis of Variance; Animals; Autoradiography; Behavior, Animal; Body Temperature; Body Weight; Brain; Chronic Disease; Dronabinol; Drug Tolerance; Enkephalins; Hyperalgesia; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Protein Precursors; Psychotropic Drugs; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome | 2000 |
Dopaminergic system does not play a major role in the precipitated cannabinoid withdrawal syndrome.
Topics: Animals; Benzazepines; Cannabinoids; Dopamine Antagonists; Dronabinol; Male; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Substance Withdrawal Syndrome | 1999 |
Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect.
Topics: Analgesics; Animals; Binding, Competitive; Conditioning, Psychological; Diprenorphine; Disulfides; Dronabinol; Drug Interactions; Enkephalin, Methionine; Extracellular Space; Male; Mice; Morphine; Motor Activity; Narcotic Antagonists; Narcotics; Neurons; Nociceptors; Nucleus Accumbens; Phenylalanine; Psychotropic Drugs; Reward; Substance Withdrawal Syndrome; Tritium | 2001 |
Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
Topics: Animals; Arachidonic Acids; Behavior, Animal; Cannabinoid Receptor Modulators; Cannabinoids; Central Nervous System; Dronabinol; Endocannabinoids; Glycerides; Male; Mice; Morphine Dependence; Motor Activity; Naloxone; Narcotic Antagonists; Neurotransmitter Agents; Receptors, Cannabinoid; Receptors, Drug; Substance Withdrawal Syndrome | 2001 |
Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Topics: Animals; Behavior, Animal; Cannabinoids; Diarrhea; Dronabinol; Drug Implants; Hallucinogens; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Inbred ICR; Mice, Knockout; Morphine; Morphine Dependence; Narcotics; Opioid Peptides; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Receptors, Opioid, mu; Rimonabant; Substance Withdrawal Syndrome | 2001 |
The psychoactive ingredient of marijuana induces behavioural sensitization.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Dronabinol; Male; Marijuana Abuse; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substance Withdrawal Syndrome | 2001 |
Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation.
Topics: Animals; Behavior, Animal; Brain; Camphanes; Cannabinoids; Densitometry; Dose-Response Relationship, Drug; Dronabinol; Immunohistochemistry; In Situ Hybridization; Lithium; Male; Morpholines; Neurons; Oxytocin; Piperazines; Proto-Oncogene Proteins c-fos; Pyrazoles; Radioimmunoassay; Rats; Rats, Long-Evans; Receptors, Cannabinoid; Receptors, Drug; Receptors, Oxytocin; Substance Withdrawal Syndrome | 2001 |
Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cannabinoids; Crosses, Genetic; Dronabinol; Drug Tolerance; Hypothermia; Marijuana Abuse; Mice; Mice, Inbred Strains; Mice, Knockout; Motivation; Motor Activity; Piperidines; Psychotropic Drugs; Pyrazoles; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Reward; Rimonabant; Spatial Behavior; Substance Withdrawal Syndrome | 2002 |
Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Topics: Administration, Oral; Animals; Benzoflavones; Dose-Response Relationship, Drug; Dronabinol; Drug Tolerance; Hallucinogens; Methanol; Mice; Motor Activity; Passiflora; Piperidines; Plant Extracts; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Solvents; Substance Withdrawal Syndrome | 2002 |
"Antagonist"-precipitated withdrawal in the rat after chronic delta9-tetrahydrocannabinol treatment.
Topics: Animals; Behavior, Animal; Body Temperature; Clomipramine; Dibenzazepines; Dronabinol; Feeding Behavior; Humans; Male; Rats; Substance Withdrawal Syndrome; Time Factors | 1978 |
Biological aspects of cannabis use.
Topics: Adolescent; Adult; Blood Pressure; Brain; Cannabis; Cell Nucleus; Dronabinol; Electroencephalography; Female; Heart Rate; Histones; Humans; Lymphocytes; Male; Middle Aged; Motivation; Neurotransmitter Agents; Neutrophils; Psychological Tests; Psychoses, Substance-Induced; Spermatozoa; Substance Withdrawal Syndrome; Substance-Related Disorders | 1978 |
The attenuation of delta 9-tetrahydrocannabinol and morphine of the quasi-morphine withdrawal syndrome in rats.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Behavior, Animal; Chlordiazepoxide; Dronabinol; Haloperidol; Humans; Male; Morphine; Morphine Dependence; Naloxone; Rats; Substance Withdrawal Syndrome | 1979 |
Interactions of thyrotropin releasing hormone and morphine sulfate in rodents.
Topics: Analgesics; Animals; Apomorphine; Behavior, Animal; Body Weight; Chlorpromazine; Dronabinol; Humans; Mice; Morphinans; Morphine; Pain; Pentobarbital; Rats; Substance Withdrawal Syndrome; Thyrotropin-Releasing Hormone | 1977 |
A potent antinociceptive cannabinoid which lacks opiate substitution properties in monkeys.
Topics: Analgesics; Animals; Blood Pressure; Cannabinoids; Dogs; Dronabinol; Haplorhini; Heart Rate; Humans; Mice; Morphine; Reaction Time; Stereoisomerism; Substance Withdrawal Syndrome | 1977 |
Naloxone-induced or postwithdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats.
Topics: Animals; Body Weight; Defecation; Dronabinol; Drug Tolerance; Female; Humans; Motor Activity; Naloxone; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders; Urination | 1977 |
Personality correlates of cannabis dependence.
Topics: Adult; Anxiety; Cannabis; Dronabinol; Humans; Male; MMPI; Personality; Social Adjustment; Substance Withdrawal Syndrome; Substance-Related Disorders | 1979 |
The effect of delta-9-tetrahydrocannabinol on barbiturate withdrawal convulsions in the rat.
Topics: Acoustic Stimulation; Animals; Barbital; Barbiturates; Dose-Response Relationship, Drug; Dronabinol; Humans; Male; Rats; Seizures; Substance Withdrawal Syndrome | 1977 |
Time course of the effects of naturally occurring cannabinoids on morphine abstinence syndrome.
Topics: Amphetamine; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Dronabinol; Humans; Levodopa; Male; Mice; Morphine Dependence; Motor Activity; Naloxone; Substance Withdrawal Syndrome | 1978 |
Effects of two cannabinoids upon abstinence signs in ethanol-dependent mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Cannabinoids; Dose-Response Relationship, Drug; Dronabinol; Electroshock; Ethanol; Humans; Male; Mice; Pyrazoles; Substance Withdrawal Syndrome | 1978 |
Great apes and rhesus monkeys as subjects for psychopharmacological studies of stimulants and depressants.
Topics: Animals; Behavior, Animal; Cannabis; Discrimination Learning; Dronabinol; Drug Tolerance; Ethanol; Haplorhini; Hominidae; Humans; Macaca; Macaca mulatta; Memory; Reinforcement, Psychology; Substance Withdrawal Syndrome; Substance-Related Disorders | 1976 |
Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice.
Topics: Animals; Cannabidiol; Cannabinoids; Cannabinol; Dronabinol; Heroin Dependence; Humans; Male; Mice; Morphine Dependence; Naloxone; Substance Withdrawal Syndrome | 1976 |
Aspects of tolerance to and dependence on cannabis.
Topics: Animals; Behavior, Animal; Cannabis; Chickens; Columbidae; Cricetinae; Dogs; Dronabinol; Drug Tolerance; Female; Haplorhini; Humans; Learning; Male; Pan troglodytes; Rabbits; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders | 1976 |
Inhibition of naloxone-induced withdrawal in morphine dependent mice by 1-trans-delta9-tetrahydrocannabinol.
Topics: Animals; Cannabis; Dose-Response Relationship, Drug; Dronabinol; Humans; Male; Mice; Morphine Dependence; Naloxone; Substance Withdrawal Syndrome | 1976 |
Attentuation of precipitated abstinence in methadone-dependent rats by delta9-THC.
Topics: Animals; Cannabis; Dronabinol; Humans; Hypnotics and Sedatives; Methadone; Rats; Research Design; Substance Withdrawal Syndrome; Substance-Related Disorders | 1976 |
Effect of delta-THC on ethanol withdrawal in mice.
Topics: Alcoholism; Animals; Cannabis; Dronabinol; Ethanol; Humans; Male; Mice; Pyrazoles; Substance Withdrawal Syndrome | 1976 |
Correlation between the in vivo and an in vitro expression of opiate withdrawal precipitated by naloxone: their antagonism by l-(-)-delta9-tetrahydrocannabinol.
Topics: Acetylcholine; Animals; Chlorpromazine; Codeine; Dose-Response Relationship, Drug; Dronabinol; Female; Guinea Pigs; Humans; Hypnotics and Sedatives; In Vitro Techniques; Male; Morphine; Motor Activity; Muscle Contraction; Muscle, Smooth; Naloxone; Pentazocine; Pentobarbital; Rats; Species Specificity; Stereoisomerism; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 1976 |
Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol.
Topics: Animals; Cannabis; Dose-Response Relationship, Drug; Dronabinol; Humans; Male; Morphine Dependence; Naloxone; Phytotherapy; Placebos; Rats; Substance Withdrawal Syndrome | 1975 |
Tetrahydrocannabinol-attenuated abstinence and induced rotation in morphine-dependent rats: possible involvement of dopamine.
Topics: Animals; Behavior; Cannabis; Dopamine; Dronabinol; Haloperidol; Humans; Male; Morphine Dependence; Naloxone; Promethazine; Rats; Stereotyped Behavior; Substance Withdrawal Syndrome; Time Factors | 1975 |
Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats.
Topics: Animals; Cannabidiol; Cannabis; Depression, Chemical; Dronabinol; Drug Synergism; Humans; Male; Morphine Dependence; Rats; Stereotyped Behavior; Substance Withdrawal Syndrome | 1975 |
Letter: Blockade of morphine abstinence by delta9-tetrahydrocannabinol.
Topics: Animals; Cannabis; Dose-Response Relationship, Drug; Dronabinol; Humans; Morphine Dependence; Phytotherapy; Rats; Substance Withdrawal Syndrome | 1975 |
Interactions between cannabidiol and delta9-THC during abstinence in morphine-dependent rats.
Topics: Animals; Cannabidiol; Cannabis; Dronabinol; Drug Synergism; Herb-Drug Interactions; Humans; Male; Morphine; Phytotherapy; Rats; Substance Withdrawal Syndrome | 1975 |
Attenuation of precipitated abstinence in methadone-dependent rats by delta 9-THC.
Topics: Animals; Behavior, Animal; Cannabis; Dronabinol; Drug Tolerance; Humans; Male; Methadone; Morphine Dependence; Naloxone; Phytotherapy; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders | 1975 |
Effects of acute and chronic administration of delta 9-tetrahy-drocannabinol or cocaine on ethanol intake in a rat model.
Topics: Alcohol Drinking; Animals; Appetitive Behavior; Circadian Rhythm; Cocaine; Conditioning, Operant; Dose-Response Relationship, Drug; Drinking; Dronabinol; Eating; Rats; Substance Withdrawal Syndrome | 1991 |
The effects of chronic treatment and withdrawal of CNS depressants on aggressive behavior.
Topics: Aggression; Animals; Behavior, Animal; Chlordiazepoxide; Dose-Response Relationship, Drug; Dronabinol; Male; Methaqualone; Mice; Morphine; Phenobarbital; Substance Withdrawal Syndrome; Trifluoperazine | 1989 |
Disruption of schedule-controlled behavior during abstinence from phencyclidine and tetrahydrocannabinol.
Topics: Animals; Appetitive Behavior; Conditioning, Operant; Dronabinol; Macaca mulatta; Phencyclidine; Rats; Reinforcement Schedule; Substance Withdrawal Syndrome | 1989 |
Benzodiazepine-like behavioral effects following withdrawal from chronic delta-9-tetrahydrocannabinol administration in rats.
Topics: Animals; Anti-Anxiety Agents; Avoidance Learning; Behavior, Animal; Benzodiazepines; Body Weight; Dronabinol; Female; Learning; Motor Activity; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome; Trimethyltin Compounds | 1989 |
The airline passenger undergoing withdrawal or overdose from narcotics or other drugs.
Topics: Adult; Aircraft; Amphetamines; Central Nervous System Depressants; Cocaine; Dronabinol; Emergencies; First Aid; Humans; Lysergic Acid Diethylamide; Male; Narcotics; Phencyclidine; Substance Withdrawal Syndrome | 1985 |
The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol.
Topics: Animals; Cannabidiol; Cannabinoids; Cannabinol; Dronabinol; Humans; Morphine; Naloxone; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome | 1985 |
Involvement of brain histamine in delta 9-tetrahydrocannabinol tolerance and withdrawal.
Topics: Animals; Behavior, Animal; Body Temperature; Brain; Dronabinol; Drug Tolerance; Histamine; Male; Povidone; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome | 1985 |
Prolonged CNS hyperexcitability in mice after a single exposure to delta-9-tetrahydrocannabinol.
Topics: Animals; Central Nervous System; Dronabinol; Drug Tolerance; Electroshock; Male; Mice; Phenobarbital; Phenytoin; Psychomotor Disorders; Seizures; Substance Withdrawal Syndrome | 1986 |
Dependence on tetrahydrocannabinol in rhesus monkeys.
Topics: Animals; Conditioning, Operant; Disease Models, Animal; Dronabinol; Drug Administration Schedule; Drug Tolerance; Macaca; Macaca mulatta; Male; Naloxone; Solvents; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 1986 |
[Obstetrical problems in drug abuse].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Amphetamine; Dronabinol; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Labor Presentation; Labor, Obstetric; Obstetric Labor Complications; Obstetric Labor, Premature; Opium; Pregnancy; Pregnancy Complications; Substance Withdrawal Syndrome; Substance-Related Disorders | 1974 |
The effect of withdrawal from cannabis on pentylenetetrazol convulsive threshold in mice.
Topics: Animals; Body Weight; Cannabis; Dronabinol; Drug Interactions; Drug Tolerance; Ethanol; Humans; Male; Mice; Pentylenetetrazole; Seizures; Substance Withdrawal Syndrome; Water Deprivation | 1974 |
[Toxicity of Indian hemp].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Atrophy; Brain; Cannabis; Cardiovascular System; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Liver; Lung; Male; Pregnancy; Psychoses, Substance-Induced; Rabbits; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders | 1973 |
[Screening procedure for barbital type physical dependence liability of psychotropic drugs in mice].
Topics: Amitriptyline; Animals; Barbiturates; Behavior, Animal; Benzazepines; Benzodiazepinones; Body Weight; Carboxylic Acids; Chlordiazepoxide; Chlorpromazine; Diazepam; Doxepin; Dronabinol; Humans; Imines; Isoquinolines; Male; Mice; Morphine; Nitrazepam; Oxazoles; Substance Withdrawal Syndrome; Substance-Related Disorders; Tranquilizing Agents | 1973 |
Morphine and delta 9-tetrahydrocannabinol: tolerance to the stimulus effects.
Topics: Animals; Cannabis; Discrimination Learning; Discrimination, Psychological; Dronabinol; Drug Antagonism; Drug Tolerance; Humans; Male; Morphine; Naloxone; Phytotherapy; Rats; Reinforcement, Psychology; Substance Withdrawal Syndrome; Substance-Related Disorders | 1974 |